KENCB10 - Avail a discount of 10% and cash back of 10% on all publications. Applicable on all licenses. Not Applicable on Ken Research Publications Limited Time Period Offer T&C apply
• Promo code can be used 1 time per user
Heart Transplant Rejection-Pipeline Review, H2 2016
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Heart Transplant Rejection-Pipeline Review, H2 2016, provides an overview of the Heart Transplant Rejection (Immunology) pipeline landscape.
Heart transplantation is the therapy used in various heart diseases. Heart transplant replaces an injured or diseased heart with a healthy one. Risk factors associated with transplantation are bleeding, infection, clots, and cardiovascular disorders. Following a transplant, the immune system may consider the transplanted heart as foreign and may work against it. Patients may hence develop complications and eventually reject the new organ. Immunosuppressive drugs are administered simultaneously which prevent the body from either identifying or attacking the foreign organ via various immune responses thus blocking organ rejection and facilitating a successful transplant.
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Heart Transplant Rejection-Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Heart Transplant Rejection (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Heart Transplant Rejection (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Heart Transplant Rejection and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Preclinical stages are 5 respectively.
Heart Transplant Rejection (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
The pipeline guide provides a snapshot of the global therapeutic landscape of Heart Transplant Rejection (Immunology).
The pipeline guide reviews pipeline therapeutics for Heart Transplant Rejection (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
The pipeline guide reviews key companies involved in Heart Transplant Rejection (Immunology) therapeutics and enlists all their major and minor projects.
The pipeline guide evaluates Heart Transplant Rejection (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
The pipeline guide reviews latest news related to pipeline therapeutics for Heart Transplant Rejection (Immunology)
Reasons to Buy
Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
Find and recognize significant and varied types of therapeutics under development for Heart Transplant Rejection (Immunology).
Classify potential new clients or partners in the target demographic.
Develop tactical initiatives by understanding the focus areas of leading companies.
Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
Formulate corrective measures for pipeline projects by understanding Heart Transplant Rejection (Immunology) pipeline depth and focus of Indication therapeutics.
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 3
Global Markets Direct Report Coverage 4
Heart Transplant Rejection Overview 5
Therapeutics Development 6
Pipeline Products for Heart Transplant Rejection-Overview 6
Pipeline Products for Heart Transplant Rejection-Comparative Analysis 7
Heart Transplant Rejection-Therapeutics under Development by Companies 8
Heart Transplant Rejection-Pipeline Products Glance 9
Early Stage Products 9
Heart Transplant Rejection-Products under Development by Companies 10
Heart Transplant Rejection-Companies Involved in Therapeutics Development 11
Astellas Pharma Inc 11
Nekonal Sarl 12
Noxxon Pharma AG 13
Pelican Therapeutics Inc 14
Heart Transplant Rejection-Therapeutics Assessment 15
Assessment by Monotherapy Products 15
Assessment by Target 16
Assessment by Mechanism of Action 18
Assessment by Route of Administration 20
Assessment by Molecule Type 22
Drug Profiles 23
AS-2521780-Drug Profile 23
Product Description 23
Mechanism Of Action 23
R&D Progress 23
emapticap pegol-Drug Profile 24
Product Description 24
Mechanism Of Action 24
R&D Progress 24
Monoclonal Antibody to Inhibit TIRC-7 for Cardiac and Kidney Transplantation-Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
PTX-15-Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
Small Molecule to Inhibit JAK3 for Heart Transplantation-Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
Heart Transplant Rejection-Dormant Projects 29
Secondary Research 30
Primary Research 30
Expert Panel Validation 30
Contact Us 30
List of Figures
Number of Products by Top 10 Targets, H2 2016 16
Number of Products by Stage and Top 10 Targets, H2 2016 16
Number of Products by Top 10 Mechanism of Actions, H2 2016 18
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 18
Number of Products by Routes of Administration, H2 2016 20
Number of Products by Stage and Routes of Administration, H2 2016 20
Number of Products by Molecule Types, H2 2016 22
List of Tables
Number of Products under Development for Heart Transplant Rejection, H2 2016 6
Number of Products under Development for Heart Transplant Rejection-Comparative Analysis, H2 2016 7
Number of Products under Development by Companies, H2 2016 8
Comparative Analysis by Early Stage Development, H2 2016 9
Products under Development by Companies, H2 2016 10
Heart Transplant Rejection-Pipeline by Astellas Pharma Inc, H2 2016 11
Heart Transplant Rejection-Pipeline by Nekonal Sarl, H2 2016 12
Heart Transplant Rejection-Pipeline by Noxxon Pharma AG, H2 2016 13
Heart Transplant Rejection-Pipeline by Pelican Therapeutics Inc, H2 2016 14
Assessment by Monotherapy Products, H2 2016 15
Number of Products by Stage and Target, H2 2016 17
Number of Products by Stage and Mechanism of Action, H2 2016 19
Number of Products by Stage and Route of Administration, H2 2016 21
Number of Products by Stage and Molecule Type, H2 2016 22
Heart Transplant Rejection-Dormant Projects, H2 2016 29
Single User License:
Corporate User License:
Astellas Pharma Inc, Nekonal Sarl, Noxxon Pharma AG, Pelican Therapeutics Inc
Heart Transplant Rejection Therapeutic Products under Development, Key Players in Heart Transplant Rejection Therapeutics, Heart Transplant Rejection Pipeline Overview, Heart Transplant Rejection Pipeline, Heart Transplant Rejection Pipeline Assessment
select a license
NEWSLETTER BY CATEGORY
The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements.... "Senior Associate, Booz Allen Hamilton"
This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"
I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"
While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"
We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"